Tag: Cancer: Prostate
FDA Approves Talzenna for Metastatic, Castration-Resistant Prostate Cancer
Significant radiographic progression-free survival seen for homologous recombination repair gene mutation, including with BRCA mutation
ASCO: Drug Combo Ups Progression-Free Survival for Metastatic Prostate Cancer
Improvement in radiographic progression-free survival seen for talazoparib plus enzalutamide as first-line treatment
Genetically Adjusted PSA Levels Improve Prediction of Prostate Cancer
Genetically adjusted prostate-specific antigen more predictive of aggressive prostate cancer than unadjusted PSA
FDA Approves Lynparza for BRCA-Mutated Metastatic Castration-Resistant Prostate Cancer
Approval is for Lynparza with abiraterone and prednisone (or prednisolone)
Transient Benefit in Outcomes Seen With Androgen Suppression + RT for Prostate Cancer
Transient clinically meaningful decline noted in EPIC hormonal and sexual domains with total androgen suppression added to radiation
Transgender Women May Be Underdiagnosed With Prostate Cancer
Findings suggest link to more aggressive disease among estrogen users, but researchers say larger studies needed
Western Diet May Have Detrimental Effect on Prostate Cancer Risk
Stronger diet effect seen in Gleason grade group >6 and in International Society of Urological Pathology grade 3 + 4 + 5 tumors
Addition of Metastasis-Directed Therapy Increases PFS in Prostate Cancer
Addition of MDT, consisting of radiation therapy, to hormone therapy results in improved progression-free survival
Germline Genetic Testing Feasible for Advanced Prostate Cancer
High satisfaction reported for genetic testing model including education, follow-up with genetic counselor
Guideline Updated for Initial Management of Advanced Prostate Cancer
Triplet therapy should be offered to patients with de novo metastatic noncastrate prostate cancer with high-volume disease
